← Leaderboards
Mandip Singh Sachdeva
Florida Agricultural And Mechanical Univ
$9,672,283
Attributed
$9,672,283
Total exposure
19
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $755.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,672,283 · 19
By mechanism
G12$3,201,999 · 10
S11$1,505,446 · 1
U54$1,469,994 · 1
P20$1,395,292 · 2
SC1$1,129,995 · 1
R16$444,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungTumorMalignant NeoplasmsIn VivoLaboratoriesAntineoplastic AgentsGrowthLung NeoplasmsNon-Small-Cell Lung CarcinomaDrug KineticsOralMolecularFutureCancer TherapyPharmaceutical PreparationsDoseIn VitroCellsToxic EffectChemotherapyDrug Delivery SystemsResearch PersonnelNude MiceCancer Patient
Grant awards (51)
Exosomal Based micro RNA delivery for Resistant Lung Cancer$148,000
R16 · FY2025 · GM · contact PI
Exosomal Based micro RNA delivery for Resistant Lung Cancer$148,000
R16 · FY2024 · GM · contact PI
Research Project 2$329,974
U54 · FY2023 · MD · contact PI
Exosomal Based micro RNA delivery for Resistant Lung Cancer$148,000
R16 · FY2023 · GM · contact PI
Research Project 2$250,973
U54 · FY2022 · MD · contact PI
Research Project 2$311,736
U54 · FY2021 · MD · contact PI
Research Project 2$317,644
U54 · FY2020 · MD · contact PI
Research Project 2$259,667
U54 · FY2019 · MD · contact PI
Research Core$155,653
P20 · FY2016 · MD · contact PI
Targeted Nanocarrier Combination Based Therapy for Lung Cancer$155,651
P20 · FY2016 · MD · contact PI
Role of Telmisartan on Intra-Tumoral Distribution of Targeted Nanoparticles$158,775
R21 · FY2015 · CA · contact PI
Targeted Nanocarrier Combination Based Therapy for Lung Cancer$158,436
P20 · FY2015 · MD · contact PI
Research Core$158,434
P20 · FY2015 · MD · contact PI
Targeted Nanocarriers for Treatment of Lung Cancer$283,240
SC1 · FY2014 · CA · contact PI
Role of Telmisartan on Intra-Tumoral Distribution of Targeted Nanoparticles$182,126
R21 · FY2014 · CA · contact PI
Targeted Nanocarrier Combination Based Therapy for Lung Cancer$145,024
P20 · FY2014 · MD · contact PI
Research Core$145,022
P20 · FY2014 · MD · contact PI
Targeted Nanocarriers for Treatment of Lung Cancer$274,480
SC1 · FY2013 · CA · contact PI
Targeted Nanocarrier Combination Based Therapy for Lung Cancer$73,692
P20 · FY2013 · MD · contact PI
Research Core$73,691
P20 · FY2013 · MD · contact PI
Targeted Nanocarriers for Treatment of Lung Cancer$292,000
SC1 · FY2012 · CA · contact PI
Targeted Nanocarrier Combination Based Therapy for Lung Cancer$164,845
P20 · FY2012 · MD · contact PI
Research Core$164,844
P20 · FY2012 · MD · contact PI
Targeted Nanocarriers for Treatment of Lung Cancer$280,275
SC1 · FY2011 · CA · contact PI
NANOMEDICINE RESEARCH CORE (NRC)$257,499
G12 · FY2011 · RR · contact PI
NANOMEDICINE RESEARCH CORE (NRC)$304,544
G12 · FY2010 · RR · contact PI
NANOMEDICINE RESEARCH CORE (NRC)$322,542
G12 · FY2009 · RR · contact PI
DRUG DELIVERY SYSTEM$166,740
G12 · FY2008 · RR · contact PI
Novel Approaches in the Treatment of Lung Cancer$184,656
S06 · FY2007 · GM · contact PI
DRUG DELIVERY SYSTEM$110,757
G12 · FY2007 · RR · contact PI
DRUG DELIVERY-SUBPRO:INHALATION DELIVERY FOR THE TREATMENT OF LUNG CANCER$55,195
G12 · FY2007 · RR · contact PI
DRUG DELIVERY SYSTEM$107,566
G12 · FY2006 · RR · contact PI
DRUG DELIVERY-SUBPRO:INHALATION DELIVERY FOR THE TREATMENT OF LUNG CANCER$53,615
G12 · FY2006 · RR · contact PI
Development of Topical Neuroinflammatory Inhibitors$312,410
S11 · FY2005 · AR
DRUG DELIVERY SYSTEM$124,206
G12 · FY2005 · RR
DRUG DELIVERY-SUBPRO:INHALATION DELIVERY FOR THE TREATMENT OF LUNG CANCER$61,901
G12 · FY2005 · RR
Development of Topical Neuroinflammatory Inhibitors$308,401
S11 · FY2004 · AR
DRUG DELIVERY SYSTEM$173,175
G12 · FY2004 · RR
INHALATION DRUG DELIVERY FOR LUNG CANCER TREATMENT$86,871
G12 · FY2004 · RR
Development of Topical Neuroinflammatory Inhibitors$295,188
S11 · FY2003 · AR
DEVELOPMENT OF CTR FOR DRUG DELIVERY: CANCER, ALZHEIMERS, BEHAVIOR$382,503
G12 · FY2002 · RR
DEVELOPMENT OF CTR FOR DRUG DELIVERY: CANCER, ALZHEIMERS, BEHAVIOR$382,503
G12 · FY2002 · RR
Development of Topical Neuroinflammatory Inhibitors$298,366
S11 · FY2002 · AR
LUNG DELIVERY OF ANTICANCER AGENTS BY HFA METERED DOSE INHALERS$0
S06 · FY2002 · GM
LUNG DELIVERY OF ANTICANCER AGENTS BY HFA METERED DOSE INHALERS$0
S06 · FY2002 · GM
DEVELOPMENT OF CTR FOR DRUG DELIVERY: CANCER, ALZHEIMERS, BEHAVIOR$382,503
G12 · FY2001 · RR
Development of Topical Neuroinflammatory Inhibitors$291,081
S11 · FY2001 · AR
Lung Delivery of Anticancer Agents--HFA Metered Inhalers$0
S06 · FY2001 · GM
LUNG DELIVERY OF ANTICANCER AGENTS BY HFA METERED DOSE INHALERS$0
S06 · FY2001 · GM
DEVELOPMENT OF CTR FOR DRUG DELIVERY: CANCER, ALZHEIMERS, BEHAVIOR$0
G12 · FY2001 · RR
DEVELOPMENT OF CTR FOR DRUG DELIVERY: CANCER, ALZHEIMERS, BEHAVIOR$229,879
G12 · FY2000 · RR